A Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Ibrutinib (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 10 Jun 2017 Biomarkers information updated
- 23 Jan 2017 Status changed from active, no longer recruiting to completed.
- 11 Feb 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016, according to ClinicalTrials.gov record.